A structured home-based exercise program (EXCAP) reduces "chemo brain" and prevents physical decline during cancer treatment.

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso ® (granisetron transdermal system) website. The website is designed to ...

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts. Read the full analysis here.

A guide to Medicare coverage for breast cancer diagnosis and treatment, including cost differences between Original Medicare and Medicare Advantage.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, Inc.'s CMO ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...

For both the fourth quarter and full year 2025, the increases in R&D expenses were primarily due to higher clinical trial and ...

The MarketWatch News Department was not involved in the creation of this content. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...